GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Gadoterate meglumine injection (CLARISCAN)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

UCSF gadolinium policy: dialysis scheduling

Product / population
UCSF institutional MRI contrast policy; the page references ACR Manual version 10.3 (2017).
Renal method
Existing hemodialysis versus peritoneal dialysis and nondialysis CKD.
Source revision
Undated policy page; references ACR 2017 version 10.3.
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Gadolinium: existing-dialysis timing differs between dated sources

The 2021 ACR-NKF abstract regards dialysis alteration as generally unnecessary after its group II/III agents. UCSF seeks prompt hemodialysis, preferably within 24 hours, for existing dialysis patients. Both distinguish this from starting prophylactic dialysis.

What to reconcile: Reconcile the agent, date and local radiology/nephrology policy. Do not delay essential imaging or initiate dialysis automatically; no agent classification is inferred from a class name.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Professional

UCSF gadolinium policy: dialysis scheduling

Open original reference

UCSF Radiology · UCSF institutional MRI contrast policy; the page references ACR Manual version 10.3 (2017).

Renal method: Existing hemodialysis versus peritoneal dialysis and nondialysis CKD.
Source date: Undated policy page; references ACR 2017 version 10.3.
Retrieved: 2026-09-07

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For patients already receiving dialysis, this policy seeks hemodialysis as soon as practical after contrast MRI, preferably within 24 hours, and notes that the normal outpatient schedule may need coordination with nephrology. It does not recommend switching peritoneal dialysis to hemodialysis or initiating prophylactic dialysis in nondialysis CKD. Dialysis does not guarantee protection from NSF. This institutional scheduling approach differs from the later ACR-NKF consensus wording about changing dialysis; keep the publication context and local coordination requirements visible.

RDM39-professional-gadoterate-clariscan-5d79d40749-C1 · Source locator: Key points: patients requiring dialysis; references

Source identity and provenance
Source family
professional_guidance
Source
https://radiology.ucsf.edu/patient-care/health-professionals/patient-safety-healthcare-professionals/mri-contrast-gadolinium-containing-policy/info
Retrieved
2026-09-07
Renal-function method
Existing hemodialysis versus peritoneal dialysis and nondialysis CKD.
Source date/version
Undated policy page; references ACR 2017 version 10.3.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
e90796f4df482ff60664c90d2455ff334288fa65fa6ac92de6ed1bd51da9948c

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=gadoterate-clariscan&s1=RDM39-professional-gadoterate-clariscan-5d79d40749&h1=9d493a1f6db95b474d2389728f9130b170e1f25cc31da16e50f58250c15170ed